relA over-expression reduces tumorigenicity and activates apoptosis in human cancer cells

British Journal of Cancer

Volumn 85, Issue 12, 2001, Pages 1914-1921

  Ricca, A ^a   Biroccio, A ^a   Trisciuoglio, D ^a   Cippitelli, M ^a,b   Zupi, G ^a   Bufalo, D Del ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Apoptosis; Breast carcinoma; relA; Tumorigenicity

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN; SYNAPTOTAGMIN; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CARCINOGENICITY; CELL ACTIVATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME DEGRADATION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

EID: 0035555653     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2001.2174     Document Type: Article

References (41)

1. High levels of c-rel expression are associated with programmed cell death in the developing avian embryo and in bone marrow cellsin vitro
2. Tumor metastasis and the reciprocal regulation of prometastatic and antimetastatic factors by nuclear factor κB
3. Expression of the NF-κB target gene IEX-1 (p22/PRG1) does not prevent cell death but instead triggers apoptosis in Hela cells
4. Function and activation of NF-κB in the immune system
5. NF-kappa B: Ten years after
6. Constitutive nuclear factor-κB-relA activation is required for proliferation and survival of Hodgkin's disease tumor cells
7. 1/S-phase transition
8. Increase of BCNU sensitivity by wt-p53 gene therapy in glioblastoma lines depends on the administration schedule
9. Bcl-2 overexpression and hypoxia synergistically act to modulate vascular endothelial growth factor expression and in vivo angiogenesis in a breast carcinoma line
10. Mutant p53 gain of function: Differential effects of different p53 mutants on resistance of cultured cells to chemotherapy
11. Selective activation of NF-kappaB by nerve growth factor through the neurotrophin receptor p75
12. Lonidamine induces apoptosis in drug-resistant cells independently of the p53 gene
13. Bcl-2 overexpression enhances the metastatic potential of a human breast cancer line
14. Hydrogen peroxide-induced apoptosis is CD95-independent, requires the release of mitochondria-derived reactive oxygen species and the activation of NF-κB
15. Clinically relevant findings
16. Nuclear factor kappa B/Rel proteins: A point of convergence of signaling pathways relevant in neuronal function and dysfunction
17. Neuroprotection by aspirin and sodium salicylate through blockade of NF-kappaB activation
18. Bcl-2 down-regulates the activity of transcription factor NF-kappaB induced upon apoptosis
19. Antisense inhibition of the p65 subunit of NF-κB blocks tumorigenicity and causes tumour regression
20. Nuclear factor-κB activity correlates with growth, angiogenesis, and metastasis of human melanoma cells in nude mice
21. The pro- or anti apoptotic function of NF-κB is determined be the nature of the apoptotic stimulus
22. Multiple mechanisms may contribute to the cellular anti-adhesive effects of phosphorothioate oligodeoxynucleotides
23. Ablation of transplanted HTLV-I Tax-transformed tumors in mice by antisense inhibition of NF-kappa B
24. Molecular mechanisms of constitutive NF-κB/Rel activation in Hodgkin/Reed-Sternberg cells
25. Mitochondrial control of apoptosis
26. Increase of cisplatin sensitivity by c-myc antisense ologodeoxynucleotides in a human metastatic melanoma inherently resistant to cisplatin
27. NF-κB functions as both a proapoptotic and antiapoptotic regulatory factor within a single cell type
28. Thiol agents and Bcl-2 identify an alphavirus-induced apoptotic pathway that requires activation of the transcription factor NF-κB
29. Constitutive activation of NK-κB during progression of breast cancer to hormone-independent growth
30. Activators and target genes of Rel/NF-κB transcription factors
31. A model for p53-induced apoptosis
32. Aberrant rel/nfκb genes and activity in human cancer
33. ADR breast cancer cells
34. Alterations in NF-κB function in transgenic epithelial tissue demonstrate a growth inhibitory role for NF-κB
35. 1 arrest and apoptosis in a pro-B cell line
36. Aberrant nuclear factor-κ/Rel expression and the pathogenesis of breast cancer
37. NF-κB: A lesson in family values
38. Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NF-κB p65 protein expression
39. NF-kappaB antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation
40. NF-kappaB activation of p53. A potential mechanism for suppressing cell growth in response to stress
41. IEX-1L, an apoptosis inhibitor involved in NF-kappaB-mediated cell survival